Telix's prostate cancer treatment Illuccix approved in Brazil
Make us a preferred source
Make us a preferred source on Google
The news: Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been approved in Brazil.
The numbers: Prostate cancer is the most commonly diagnosed male cancer in Brazil with an estimated 71,730 new cases in 2023, according to figures from the Brazilian Cancer Institute.
Prostate cancer was also the second most common cause of cancer death in men, after lung cancer, with around 20,000 men dying from the disease in 2022.
The context: The marketing authorisation by Brazil's health regulatory agency, ANVISA, makes Illuccix the first and only prostate cancer imaging agent of its kind to receive full regulatory approval in the country.
Telix has provided Brazil's GSH Corp Participações with an exclusive licence to manufacture, distribute and market Illuccix in Brazil, through its subsidiary R2PHARMA.
Telix will also form a joint venture with R2PHARMA to commercialise and distribute Telix's therapeutic and diagnostic radiopharmaceutical products in Brazil, building on the two companies' existing partnership since 2019.
Illuccix is already commercially available in Australia, Canada, New Zealand and the US, and has recently been approved in the UK and multiple EU countries.
What they said: "Telix is pleased to bring Illuccix to Brazil and Latin America, with this new imaging modality now recognized in leading clinical practice guidelines and already being adopted in other parts of the world," said Telix international CEO Raphaël Ortiz.
The source: ASX
